Last reviewed · How we verify
NCT04313218
Carbetocin Versus Misoprostol. A Retrospective Comparative Study
trial testing Carbetocin in Cesarean Section Complications in 300 participants. Completed in 28 February 2020.
1 February 2020
Quick facts
| Lead sponsor | Port Said University hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2018 |
| Primary completion | 1 February 2020 |
| Estimated completion | 28 February 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Carbetocin (CARBETOCIN) — full drug profile →
Conditions studied
- Cesarean Section Complications — all drugs for Cesarean Section Complications →
Sponsor
Port Said University hospital
Who can join
Eligibility, female only, with Cesarean Section Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cesarean section is one of the most common surgeries practiced for save delivery of the fetus, however it is not a safe route of delivery its incidence is rising especially in high and middle income countries. The major concern is that the average blood loss during cesarean delivery is 487 ml, this amount is too close to the definition of postpartum hemorrhage by WHO as loss of 500 cc of blood in the first 24 hours after delivery making control of blood loss during cesarean delivery crucial to decrease maternal morbidities.This study aim to compare the use of misoprostol to carbetocin in reducing blood loss during cesarean section in low risk patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04313218
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Carbetocin
Trials testing the same drug.
- NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
- NCT06946589 — Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section · Phase 4 · not yet recruiting
- NCT06776926 — Timing of Carbetocin Administration in Postpartum Hemorrhage · NA · completed
- NCT06692621 — Effects of Carbetocin and Oxytocin Used in Cesarean Sections on Postoperative Pain · completed
- NCT07380529 — Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesar · NA · completed
Other recruiting trials for Cesarean Section Complications
Currently open trials in the same condition.
- NCT07278037 — Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage · recruiting
- NCT05224726 — Platelet Rich Plasma for Uterine Scar · NA · recruiting
- NCT07130747 — Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section · NA · recruiting
- NCT05791630 — The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) · NA · recruiting
- NCT07049705 — Factors Influencing Bradycardia During Spinal Anesthesia in Obstetric Patients Undergoing Cesarean Section · active not recruiting
Other Port Said University hospital trials
Trials by the same sponsor.
- NCT06828497 — Analgesic Efficacy of Quadratus Lumborum Block Against Erector Spinae Plane Block in Laparoscopic Sleeve Gastrectomy · NA · completed
- NCT06745986 — Ultrasound-Guided Fascia Iliaca Compartmental Block Versus Spinal Anesthesia in Femoral Thrombectomy · Phase 4 · completed
- NCT04507191 — PDL1 in Ovarian High Grade Serous Carcinoma · completed
- NCT04284631 — Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04313218 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Port Said University hospital
- Last refreshed: 18 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04313218.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing